{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 38,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide serves as a company overview/fact sheet.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/5",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.35,
        "y": 0.08
      },
      "kind": "image",
      "text": "calliditas THERAPEUTICS",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c68707a-3e05-4dcc-b4e4-de45d93b3714",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "Part A of Pivotal Phase 3 trial in IgAN fully recruited with topline readout expected in 4Q 2020; anticipated NDA and MAA filings in 1H 2021 for accelerated approval in U.S. and conditional approval in E.U.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a5a9098-8e4c-4804-86fd-300c03ccebbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Key institutional shareholders include: Industrifonden (swe), Investinor (nor), BVF Capital, Vivo Capital, Sofinnova Partners",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4e0f38f-e927-467f-b977-8d1725699095",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "list",
      "text": "Headquartered in Stockholm, Sweden; listed on OMX NASDAQ in Sweden – Midcap segment (ticker: CALTX)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca2d5a88-c2ba-49b8-8622-386cb49c7c73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Lead product candidate, Nefecon, being developed for the treatment of IgA Nephropathy (IgAN), a serious progressive autoimmune disease of the kidney with no currently approved treatments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5f37006-9c76-4348-8125-d0af7bfcb16e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Market cap as of May 27, 2020: ~US$392 million; Cash balance as of March 31, 2020: US$77 million, providing financing into 2H 2021 through planned regulatory filings for marketing approval in the U.S. and E.U.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9aa16ce-dbe3-4005-ac1b-6d3f3b223ec0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "A clinical-stage biopharma company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet needs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f357fa49-4f6f-4138-8236-8d76c7ceda6d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e1fd9b43-efe4-43e2-adee-4b9fad1793ba",
      "evidence": "The slide contains a list of key points, which is a common format for an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "686cfed0-ff02-48b3-99c9-38eb0b1db6fc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Team",
      "beatSlug": "sequoia-pitch-team",
      "evidence": "The document presents the management team and board of directors.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}